Current Status and Growth of Nuclear Theranostics in Singapore
- 23 Downloads
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
KeywordsTheranostic Singapore Radioiodine Lutetium Yttrium Radium
We wish to acknowledge the invaluable contributions of our radiopharmaceutical laboratory staff, nurses, nuclear medicine technologists and managers, without whom, none of our nuclear theranostic efforts will be possible.
Compliance with Ethical Standards
Conflict of Interest
Hian Liang Huang, Aaron Kian Ti Tong, Sue Ping Thang, Sean Xuexian Yan, Winnie Wing Chuen Lam, Kelvin Siu Hoong Loke, Charlene Yu Lin Tang, Lenith Tai Jit Cheng, Gideon Su Kai Ooi, Han Chung Low, Butch Maulion Magsombol, Wei Ying Tham, Charles Xian Yang Goh, Colin Jingxian Tan, Yiu Ming Khor, Sumbul Zaheer, Pushan Bharadwaj, Wanying Xie and David Chee Eng Ng declare no conflict of interest.
Ethical approval is not required for this work.
- 3.Parmeswaran R. Multidisciplinary care for well differentiated thyroid cancer. 2016. http://emss.org.sg/wp-content/uploads/2017/10/Thyroid-Cancer-Consensus-SG-Quick-Reference-Guide.pdf. Accessed 26 December 2018.
- 8.Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90(2):220–6. https://doi.org/10.1159/000225951.CrossRefPubMedGoogle Scholar
- 9.Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European neuroendocrine tumour society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2017 Nov;20.Google Scholar
- 13.Yan SX, Lim GK. Optimizing reconstruction algorithm to improve quality of post-PRRT Yittrium-90 PET scan. Neuroendocrinology. 2018;106(suppl 1):1–301.Google Scholar
- 16.NCC website: https://www.nccs.com.sg. Accessed 26 December 2018.
- 17.Lam WWC, Goh C, Chua MLK, Tan J. 270P 68Ga prostate-specific membrane antigen positron emission tomography for evaluation of biochemical recurrence of prostate cancer - our local experience. Ann Oncol. 2017;28(suppl_10). https://doi.org/10.1093/annonc/mdx662.009.
- 22.Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.CrossRefPubMedGoogle Scholar
- 27.Heck MM, Retz M, D‘Alessandria C, et al. Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196:382–91.Google Scholar
- 32.Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4222-x.
- 33.Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.11.016.